464913-33-5

Basic information

• Product Name: 3-[(2-ETHOXY-3,4-DIOXO-1-CYCLOBUTEN-1-YL)AMINO]-2-HYDROXY-N,N-DIMETHYL-BENZAMIDE
• Synonyms: 3-[(2-ETHOXY-3,4-DIOXO-1-CYCLOBUTEN-1-YL)AMINO]-2-HYDROXY-N,N-DIMETHYL-BENZAMIDE;Benzamide,3-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]-2-hydroxy-N,N-dimethyl-;3-((2-Ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)-2-hydroxy-N,N-dimethylbenzamide
• CAS NO: 464913-33-5
• Molecular Formula: C₁₅H₁₆N₂O₅
• Molecular Weight: 304.3
• Mol File: 464913-33-5.mol

Chemical Properties

• Boiling Point: 502.255°C at 760 mmHg
• Flash Point: 257.555°C
• Appearance: /
• Density: 1.384g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.618
• PKA: 7.93±0.50(Predicted)
• CAS DataBase Reference: 3-[(2-ETHOXY-3,4-DIOXO-1-CYCLOBUTEN-1-YL)AMINO]-2-HYDROXY-N,N-DIMETHYL-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(2-ETHOXY-3,4-DIOXO-1-CYCLOBUTEN-1-YL)AMINO]-2-HYDROXY-N,N-DIMETHYL-BENZAMIDE(464913-33-5)
• EPA Substance Registry System: 3-[(2-ETHOXY-3,4-DIOXO-1-CYCLOBUTEN-1-YL)AMINO]-2-HYDROXY-N,N-DIMETHYL-BENZAMIDE(464913-33-5)

Safety Data

• Hazardous Substances Data: 464913-33-5(Hazardous Substances Data)

Usage

General Description

3-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]-2-hydroxy-N,N-dimethyl-benzamide is a chemical compound with a complex molecular structure. It contains an ethoxy group, a cyclobuten-1-yl group, an amino group, and a benzamide group. The compound also contains a hydroxy group and two dimethyl groups. The presence of these functional groups gives the compound a variety of potential biological and chemical properties. It may have applications in pharmaceuticals, organic synthesis, or other fields where complex molecular structures with specific functional groups are needed.

InChI:InChI=1/C15H16N2O5/c1-4-22-14-10(12(19)13(14)20)16-9-7-5-6-8(11(9)18)15(21)17(2)3/h5-7,16,18H,4H2,1-3H3

Upstream product

• 464913-11-9 3-amino-2-hydroxy-N,N-dimethylbenzamide 
• 5231-87-8 3,4-diethoxy-3-cyclobuten-1,2-dione 
• 25910-91-2 3,4-diethoxycyclobutane-1,2-dione 
• 1000993-70-3 2-hydroxy-N,N-dimethyl-3-amino-benzamide hydrochloride 
• 35748-36-8 2-hydroxy-3-nitrobenzoyl chloride 
• 85-38-1 3-nitrosalicylic acid 
• 66952-65-6 2-hydroxy-N,N-dimethyl-3-nitrobenzamide 

Downstream Products

• 1000993-46-3 3-[[2-[[1(R)-(4-bromo-5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamid 
• 1000993-51-0 2-hydroxy-N,N-dimethyl-3-[[2-[[(R)-[5-methyl-4-(1-methylethyl)-2-furanyl]propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]-benzamide 
• 1092388-84-5 3-{3,4-dioxo-2-[(tetrahydrofuran-2-ylmethyl)amino]cyclobut-1-enylamino}-2-hydroxy-N,N-dimethylbenzamide 
• 1092389-21-3 2-hydroxy-N,N-dimethyl-3-{2-[(R)-1-(5-methyltetrahydrofuran-2-yl)propylamino]-3,4-dioxocyclobut-1-enylamino}benzamide 
• 1092389-20-2 2-hydroxy-N,N-dimethyl-3-{2-[(R)-1-((2R,5S)-5-methyltetrahydrofuran-2-yl)propylamino]-3,4-dioxocyclobut-1-enylamino}benzamide 
• 1193343-86-0 3-(2-(2-ethyl-2-(4-fluorobenzoyl)hydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide 
• 1193343-79-1 3-(2-(2,2-diethylhydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide 
• 473725-27-8 3-{2-[(R)-1-(4-fluoro-phenyl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-2-hydroxy-N,N-dimethyl-benzamide 
• 1193343-94-0 tert-butyl 2-(2-(3-(dimethylcarbamoyl)-2-hydroxyphenylamino)-3,4-dioxocyclobut-1-enyl)-2-ethylhydrazinecarboxylate 
• 1193343-83-7 3-(2-(2-ethyl-2-(4-methoxyphenyl)hydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide 
• 1193343-82-6 3-(2-(2-ethyl-2-(4-fluorophenyl)hydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide 
• 1193343-81-5 3-(2-(2-ethyl-2-phenylhydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethyl benzamide 
• 1193343-80-4 3-(2-(2-acetyl-2-ethylhydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide 
• 1193343-84-8 3-(2-(2-ethyl-2-(pyridin-2-yl)hydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide 

Relevant articles and documents

3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.

Bicyclo[2.2.1]heptane containing: N, N ′-diarylsquaramide CXCR2 selective antagonists as anti-cancer metastasis agents

CXCR1 and CXCR2 are CXC chemokine receptors (CXCRs), corresponding to cytokines of the CXC chemokine family. CXCR2 was found to be 77% homologous to CXCR1. Antagonism of the chemokine receptor CXCR2 has been proposed as a new strategy for the treatment of

NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.

NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the tr

DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the

NOVEL HYDRAZINO-CYCLOBUT-3-ENE-1, 2-DIONE DERIVATIVES AS CXCR2 ANTAGONISTS

The present invention relates to novel hydrazino-cyclobut-3-ene-1,2-dione compounds of Formula (I) as selective CXCR2 antagonists, pharmaceutical compositions containing the novel compounds, as well as methods for treating or preventing chemokine mediated

3, 4-DI-SUBSTITUTED CYCLOBUTENE- 1, 2 -DIONES AS CXCR2 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I) wherein R1, R2, Ar, p, R4 and R5 are as defined herein, which are useful for creating diseases which respond to CXCR2 receptor mediators. Pharmaceutical

PROCESS FOR CONTROLLED CRYSTAL SIZE IN 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS

This application discloses a novel process for the preparation of 2-Hydroxy-N,N-dimethyl-3-[[2-[[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide, which has utility, for example, in the treatment of CXC chemokine-mediated diseases.

PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS

This application discloses a novel process for the preparation of 1.2 - substituted 3, 4 - dioxo - 1 - cyclobutene compounds of formula (A), which have utility, for example, in the treatment of CXC chemokine -mediated diseases, and intermediates useful in the synthesis thereof.

Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists

We describe herein a novel series of 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective inhibitors against the CXCR2 chemokine receptor and IL-8-mediated chemotaxis of a CXCR2-expressing cell line. Furthermore, these alkyl-hydrazine series inhibitors such as 5b demonstrated acceptable metabolic stability when incubated in human and rat microsomes.